Alembic Pharmaceuticals will be in focus after securing final USFDA approval for Diltiazem Hydrochloride Tablets, a widely used treatment for high blood pressure and angina. The drug is deemed therapeutically equivalent to Bausch Health’s Cardizem. With this approval, Alembic’s total ANDA count rises to 230. The stock closed at Rs 904.20 on Friday, down 14% so far in 2025.